Treatment × baseline glycometabolic status: Relative risk reduction $p_{interaction}$=0·98 | Absolute risk reduction $p_{interaction}$=0·0019

Subgroup	MACE incidence Alirocumab n/N (%)	MACE incidence Placebo n/N (%)	HR (95% CI)	ARR (95% CI)
Overall	903/9462 (9·5)	1052/9462 (11·1)	0·85 (0·78, 0·93)	1·6% (0·7%, 2·4%)
Normoglycaemia	192/2639 (7·3)	220/2595 (8·5)	0·85 (0·70, 1·03)	1·2% (–0·3%, 2·7%)
Prediabetes	331/4130 (8·0)	380/4116 (9·2)	0·86 (0·74, 1·00)	1·2% (0%, 2·4%)
Diabetes	380/2693 (14·1)	452/2751 (16·4)	0·84 (0·74, 0·97)	2·3% (0·4%, 4·2%)



